Account
Insider Insights
28.02.2022
UK first rare disease action plan

On 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...

Read more
Insider Insights
01.02.2022
NICE changes to its methods and processes

The changes cover how topics are chosen, the steps and stages in each evaluation and how evidence is...

Read more
Insider Insights
01.02.2022
Proposals for reforming public and private health

The report looks at four possible scenarios including most notably the creation of a “grande Sécu...

Read more
Insider Insights
01.02.2022
Proposals aimed at building together our future

The association proposes concentrating efforts around four primary objectives.

Read more
Insider Insights
01.02.2022
Germany completes early benefit assessments

In addition to new cancer drugs, the G-BA also evaluated the first antiviral drug to treat COVID-19 ...

Read more
Insider Insights
01.02.2022
Early access granted to Xevudy

Notably, the early access scheme was reformed with effect from 1st July 2021.

Read more
Articles
27.01.2022
Early access schemes in France

The 2021 Social Security Law made provision for overhauling the early scheme in France. As of 1st Ju...

Read more
Articles
07.12.2021
What are the 5 Pricing & Market Access trends ...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
Articles
22.09.2021
Commercial arrangements in access to medicine

The introduction of new medicines in England requires the cooperation of industry and the NHS.

Read more
Articles
04.08.2021
ICER puts spotlight on health insurers

ICER recently outlined its plans to annually assess Barriers to Fair Access within prescription drug...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.